MyMyelomaTeam

Maintenance therapy for multiple myeloma (MM) post-bone marrow transplant (BMT) aims to prolong remission and improve overall survival. For standard-risk MM patients with renal problems, lenalidomide (Revlimid) is often recommended due to its effectiveness and relatively well-tolerated side effects. However, renal function Show Full Answer

Maintenance therapy for multiple myeloma (MM) post-bone marrow transplant (BMT) aims to prolong remission and improve overall survival. For standard-risk MM patients with renal problems, lenalidomide (Revlimid) is often recommended due to its effectiveness and relatively well-tolerated side effects. However, renal function must be closely monitored, and dosage adjustments may be necessary.

Key points:
- Lenalidomide: Effective and well-tolerated, but requires monitoring and possible dosage adjustments for renal issues.
- Adherence: Sticking to the maintenance plan is crucial for the best outcomes.
- Side Effects: Discuss potential side effects and management strategies with your oncologist.

Always consult with your healthcare provider to tailor the best maintenance therapy for your specific condition.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

6 Facts About Myeloma Maintenance Therapy | MyMyelomaTeam